open access

Vol 3, No 5 (2007)
Review paper
Published online: 2007-10-17
Get Citation

Mantle cell lymphoma - optimal therapy choice based on clinical trial results

Wojciech Jurczak, Jan Walewski
Onkol. Prak. Klin 2007;3(5):254-258.

open access

Vol 3, No 5 (2007)
REVIEW ARTICLES
Published online: 2007-10-17

Abstract

Mantle cell lymphoma (MCL) develops resistance and becomes refractory to therapy, which makes it´s clinical course different from so called "indolent lymphomas", were prognosis is relatively good, despite multiple relapses. Consolidation approach offered to patients in complete or very good partial regression after the Ist line therapy gives the best chance to cure the disease. Although the response rate is increased and event free survival is prolonged after Rituximab containing regimens, it is not enough to cure MCL. High dose therapy with stem cell support (ASCT) is the standard I-st line approach feasible for most younger patients (< 60 years). MCL is the disease of the elderly where intensive treatment modalities are limited by patients´ general status and co-morbidities. Radiotherapy is an effective consolidation method in a rare cases diagnosed in I/II clinical stage. For those in advanced clinical stage, radioimmunotherapy could be an alternative consolidation method, allowing for a "total tumor" radiotherapy without the necessity of the transplant procedure.

Abstract

Mantle cell lymphoma (MCL) develops resistance and becomes refractory to therapy, which makes it´s clinical course different from so called "indolent lymphomas", were prognosis is relatively good, despite multiple relapses. Consolidation approach offered to patients in complete or very good partial regression after the Ist line therapy gives the best chance to cure the disease. Although the response rate is increased and event free survival is prolonged after Rituximab containing regimens, it is not enough to cure MCL. High dose therapy with stem cell support (ASCT) is the standard I-st line approach feasible for most younger patients (< 60 years). MCL is the disease of the elderly where intensive treatment modalities are limited by patients´ general status and co-morbidities. Radiotherapy is an effective consolidation method in a rare cases diagnosed in I/II clinical stage. For those in advanced clinical stage, radioimmunotherapy could be an alternative consolidation method, allowing for a "total tumor" radiotherapy without the necessity of the transplant procedure.
Get Citation

Keywords

mantle cell lymphoma; chemoimmunotherapy; radioimmunotherapy

About this article
Title

Mantle cell lymphoma - optimal therapy choice based on clinical trial results

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 5 (2007)

Article type

Review paper

Pages

254-258

Published online

2007-10-17

Bibliographic record

Onkol. Prak. Klin 2007;3(5):254-258.

Keywords

mantle cell lymphoma
chemoimmunotherapy
radioimmunotherapy

Authors

Wojciech Jurczak
Jan Walewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl